These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28986660)

  • 1. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
    Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
    Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
    D'Haens G; Vermeire S; Lambrecht G; Baert F; Bossuyt P; Pariente B; Buisson A; Bouhnik Y; Filippi J; Vander Woude J; Van Hootegem P; Moreau J; Louis E; Franchimont D; De Vos M; Mana F; Peyrin-Biroulet L; Brixi H; Allez M; Caenepeel P; Aubourg A; Oldenburg B; Pierik M; Gils A; Chevret S; Laharie D;
    Gastroenterology; 2018 Apr; 154(5):1343-1351.e1. PubMed ID: 29317275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time of infliximab therapy initiation and dose escalation in Crohn's disease.
    Lam MC; Lee T; Atkinson K; Bressler B
    World J Gastroenterol; 2014 Jan; 20(1):214-8. PubMed ID: 24415874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
    Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
    J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
    Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
    Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
    Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China.
    Li Y; Shu HJ; Lu H; Yang H; Li J; Tan B; Qian JM
    J Dig Dis; 2017 Jul; 18(7):388-394. PubMed ID: 28644565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
    D'Haens G; Reinisch W; Colombel JF; Panes J; Ghosh S; Prantera C; Lindgren S; Hommes DW; Huang Z; Boice J; Huyck S; Cornillie F;
    J Crohns Colitis; 2017 Jun; 11(6):680-689. PubMed ID: 28025307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea.
    Seo H; Ye BD; Song EM; Lee SH; Chang K; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK
    Dig Dis Sci; 2017 Oct; 62(10):2882-2893. PubMed ID: 28822006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission.
    Reenaers C; Mary JY; Nachury M; Bouhnik Y; Laharie D; Allez M; Fumery M; Amiot A; Savoye G; Altwegg R; Devos M; Malamut G; Bourreille A; Flourie B; Marteau P; Vuitton L; Coffin B; Viennot S; Lambert J; Colombel JF; Louis E;
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):234-243.e2. PubMed ID: 28993262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical predictors of thiopurine-related adverse events in Crohn's disease.
    Moran GW; Dubeau MF; Kaplan GG; Yang H; Eksteen B; Ghosh S; Panaccione R
    World J Gastroenterol; 2015 Jul; 21(25):7795-804. PubMed ID: 26167079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
    Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease.
    Dupont-Lucas C; Sternszus R; Ezri J; Leibovitch S; Gervais F; Amre D; Deslandres C
    J Crohns Colitis; 2016 Jul; 10(7):795-804. PubMed ID: 26822611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.